New Data on Esketamine Nasal Spray as Treatment for Adolescents Contemplating Suicide
These important findings on esketamine nasal spray as a treatment for young individuals with suicidal ideation were presented at the ACNP 2023 Annual Meeting. We interviewed the vice president and head of neuropsychiatry clinical development at Johnson & Johnson Innovative Medicine to learn more.
Neuromodulation for Nicotine Use in Schizophrenia
What neuromodulation can be used to specifically target nicotine users with schizophrenia? This research may tell us.
Adjunctive Cariprazine in Treating Major Depressive Disorder
This ACNP 2023 Annual Meeting poster covered a 26-week study on cariprazine as an adjunctive treatment to antidepressants in patients with major depressive disorder.
Using Brain Science to Develop Better, Safer, More Effective Treatments
Deep brain stimulation for substance use disorders when everything else fails, the history of the ACNP, and more.
The First Step: A Schizophrenia-Specific Intervention for Nicotine Use
Research presented at the ACNP 2023 Annual Meeting shows that neuromodulation therapy cTBS could be a viable schizophrenia-specific intervention for nicotine use.
Amotivation in Individuals with Schizophrenia: Exciting Research Ideas at ACNP 2023 Annual Meeting
Exciting research ideas are stirring at the ACNP 2023 Annual Meeting.
Neurosteroid Therapeutics “Offer Great Promise” in Postpartum Depression
Neurosteroid therapeutics could be the solution to provide fast-acting treatment for mothers with postpartum depression.
Takeaways on Cognitive Impairment in Schizophrenia from ACNP 2023 Annual Meeting
Check out these brief summaries on cognitive impairment in schizophrenia from an excellent session at the ACNP 2023 Annual Meeting!
“A Little Bit Science, A Little Bit Manifesto”: Deep Brain Stimulation in Psychiatry
DBS in psychiatry: What challenges stand between this treatment and success? Alik Widge, MD, PhD, shares more at the ACNP 2023 Annual meeting.
Making a Real Difference: Biomarkers and Novel Treatment Development for Serious Mental Illness
Did you catch the President's Plenary at the ACNP 2023 Annual Meeting?
Navacaprant: A Hot Topic at the ACNP 2023 Annual Meeting
Navacaprant—a novel, oral, once-daily, highly selective kappa opioid receptor antagonist that is currently in phase 3 development as a monotherapy for major depressive disorder.
Eating Disorders and Emerging Neuroscience
Don't miss this ACNP 2023 Annual Meeting session!
2 Commerce Drive Cranbury, NJ 08512